Page 5 - Stephens Yoder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220

Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.

United statesStephens yoderMaria kelmanPieris pharmaceuticalsCompany quarterly reports on formCompany annual report on formExchange commissionSecurities exchangePieris pharmaceuticals incLooking statementsSecurities actSecurities exchange actAnnual reportQuarterly reportsRelations contactUnited states wire group

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

United statesStephens yoderMaria kelmanPieris pharmaceuticalsCompany quarterly reports on formBoston pharmaceuticalsExchange commissionCompany annual report on formSecurities exchangePieris pharmaceuticals incChief executive officerAstrazeneca collaborationServier collaborationQuarter financial updateToll freeSecurities act

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDTAdjustments to PRS-060/AZD1402 phase 2 study design boost enrollment rate and facilitate a topline readout by 3Q23Cinrebafusp

United statesStephens yoderMaria kelmanPieris pharmaceuticalsBoston pharmaceuticalsCompany quarterly reports on formExchange commissionCompany annual report on formSecurities exchangePieris pharmaceuticals incChief executive officerAstrazeneca collaborationServier collaborationQuarter financial updateToll freeSecurities act

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

United statesStephens yoderMaria kelmanPieris pharmaceuticalsCompany quarterly reports on formBoston pharmaceuticalsExchange commissionCompany annual report on formSecurities exchangePieris pharmaceuticals incCompany to hostInvestor conference call on wednesdayChief executive officerAstrazeneca collaborationServier collaborationQuarter financial update

Pieris Pharmaceuticals, Inc : Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDTBOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology

United statesStephens yoderMaria kelmanPieris pharmaceuticalsBoston pharmaceuticalsCompany quarterly reports on formExchange commissionCompany annual report on formSecurities exchangePieris pharmaceuticals incCompany to hostInvestor conference call on wednesdayChief executive officerAstrazeneca collaborationServier collaborationQuarter financial update